Table 2

Participants with CD4+ T cell Rsps to 6 melanoma helper peptides vaccine

High durable T cell Rsp in PBMCDurable T cell Rsp in PBMCRsp in PBMChRsp in PBMCRsp in SINRsp in PBMC by week 13 or in SIN
#/n (%)(90% CI)**#/n (%)(90% CI)**#/n (%)(90% CI)**#/n (%)(90% CI)**#/n (%)#/n (%)
PD-1 Ab naïve1/6 (17%)(1 to 58)1/6 (17%)(1 to 58)4/6 (67%)(27 to 94)3/6 (50%)(15 to 85)0/3 (0%)4/6 (67%)
PD-1 Ab experienced0/16 (0%)(0 to 17)1/16 (6%)(0 to 26)2/16 (12.5%)(2 to 34)2/16 (12.5%)(2 to 34)1/7 (14%)†3/16 (19%)
All participants1/22 (4.5%)(0 to 20)2/22 (9%)(2 to 26)6/22 (27%)(13 to 47)5/22 (23%)(9 to 42)1/10 (10%)†7/22 (32%)
  • *The Clopper-Pearson exact method was used to generate 90% CIs.

  • †This participant met criteria for both Rsp and hRsp in the SIN.

  • Ab, antibody; hRsp, high T cell response; PBMC, peripheral-blood mononuclear cell; PD-1, programmed cell death protein 1; Rsp, any T cell response; SIN, sentinel immunized node.